Amy C. Moore, Director of Patient Engagement and Advocacy at Summit Therapeutics, shared on LinkedIn:
“In a previous post, we discussed that simply living longer may not be the only thing or even the most important consideration for patients when evaluating a new treatment option. Quality of life is also important, and that was especially evident in listening to the discussions and talking with attendees at this weekend’s EGFR conference in Chicago.
In this week’s Oncoflash Stat Saturday post, the author discusses how to look beyond just the p value to determine if a study is clinically meaningful as well.
I appreciate these resources as tools to prompt education and discussion as we all work toward our collective goal of improving outcomes for patients impacted by cancer.”
Other articles featuring Amy C. Moore on OncoDaily.